Camp4 secures TGA clearance for CMP-002 trial.

Camp4 Therapeutics received Australian regulatory approval to begin a Phase 1/2 clinical trial of CMP-002 for SYNGAP1 disorder. This milestone enables a second private offering that could raise up to $50 million.